Brian Price, MD
Interventional Cardiology · Glasgow, KYNPI 1962536953
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Penumbra, Inc. at 38.8% of the total. Reporting peaked in 2022 at $12,948 and has fallen 79.8% since, to $2,614 in 2025.
Across 312 payments — averaging $78.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$9K
- Abbott$6K
- Cardiovascular Systems Inc.$2K
- Medtronic$2K
- Boston Scientific$910
- EKOS Corporation$838
- plus $4K from 28 others
What the payments were for
- Speaking & faculty fees$8,40034%
- Travel & lodging$5,12821%
- Food & beverage$10,91045%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 15 | $9,475 |
| Abbott | 50 | $5,505 |
| Cardiovascular Systems Inc. | 32 | $2,060 |
| Medtronic(2 entities) | 13 | $1,902 |
| Boston Scientific | 19 | $910 |
| EKOS Corporation | 4 | $838 |
| Inari Medical, Inc. | 9 | $624 |
| Johnson & Johnson | 42 | $583 |
| Novartis | 26 | $496 |
| Amgen | 17 | $343 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $213 |
| Teleflex LLC | 7 | $207 |
| Sanofi-aventis U.S. LLC | 12 | $176 |
| Esperion Therapeutics, Inc. | 4 | $172 |
| Chiesi USA, Inc. | 5 | $140 |
| Abiomed | 6 | $134 |
| Livanova USA, Inc. | 2 | $129 |
| AstraZeneca | 7 | $100 |
| Pfizer | 5 | $67 |
| Boehringer Ingelheim | 4 | $53 |
| Novo Nordisk | 2 | $39 |
| Philips North America LLC | 1 | $39 |
| Lundbeck LLC | 2 | $36 |
| Merck | 2 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| BD | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Stryker | 1 | $18 |
| Cardinal Health 200 LLC | 1 | $16 |
| Biotronik Inc. | 1 | $16 |
| Portola Pharmaceuticals, LLC | 1 | $15 |
| Verge Medical, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$9,091
- PERCLOSE PROGLIDE$1,804
- SUPERA$1,772
- Resolute$1,352
- Peripheral Orbital Atherectomy System$1,170
- EKOSONIC$821
- FLOWTRIEVER CATHETER, S$787
- GENERAL VASCULAR INTERVENTION$586
- DRAGONFLY OPSTAR$271
- CT THROMBECTOMY SYSTEM KIT$240
- JETi Peripheral Catheter$181
- Endurant$166
- ESPRIT$159
- Interventional Products$132
- NEXLIZET$125
- NEXLETOL$125
- JETI$116
- Coronary Orbital Atherectomy System$107
- Repatha$107
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$100
How this compares
$24,438 in reported general payments places this provider in the 80th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 72 | $91,008 |
| EntrestoSacubitril/Valsartan | 22 | $27,945 |
| XareltoRivaroxaban | 18 | $14,473 |
| Repatha SureclickEvolocumab | 23 | $13,946 |
| FarxigaDapagliflozin Propanediol | 15 | $13,582 |
| BrilintaTicagrelor | 21 | $12,079 |
| Praluent PenAlirocumab | 25 | $11,665 |
| Repatha SyringeEvolocumab | 12 | $6,677 |
| Ranolazine ErRanolazine | 17 | $1,333 |
| Atorvastatin Calcium | 126 | $1,178 |
| Metoprolol Succinate | 97 | $1,039 |
| Rosuvastatin Calcium | 113 | $1,037 |
| ClopidogrelClopidogrel Bisulfate | 77 | $862 |
| Prasugrel Hcl | 11 | $684 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 17 | $585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $67 | $91,00872 claims |
| NovartisEntresto | $496 | $27,94522 claims |
| AstraZenecaFarxiga, Brilinta | $100 | $25,66136 claims |
| Johnson & JohnsonXarelto | $583 | $14,47318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Glasgow
- Amit SrivastavaEdgewood$642K
- Avichai EresLexington$616K
- Steve LinLexington$362K
- Daniel StewartLouisville$290K
- Robert SawyerLexington$249K
- Ganesh Keshav ThirunavukkarasuLexington$220K
- Daniel RothschildLouisville$154K
- Naresh SolankhiLouisville$132K
- Ashish RastogiOwensboro$123K
- Armaghan SoomroLexington$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.